论文部分内容阅读
Objective:To compare the antiplatelet effect and major adverse cerebrovascular events of Pipeline for intracranial aneurysms using glycoprotein Ⅱb/Ⅲa antagonists(GPI)eptifibatide and tirofiban.Methods:Retrospective analysis of relevant data of patients using GPIs combined with oral antiplatelet therapy in Nanfang Hospital of Southern Medical University from December 2017 to December 2019.The study was approved by the ethics Committee of Nanfang Hospital of Southern Medical University.According to the random use of GPIs drugs,they were assigned to the eptifibatide group and tirofiban group.Basic data,platelet inhibition rates at baseline,24h and 72h after administration,short-term major adverse cerebrovascular events,and bleeding complications were compared between the two groups.Results:A total of 47 patients were included in this study,including 24 patients in eptifibatide group and 23 patients in tirofiban group.There was no significant difference in average age(53.75 vs.53.91 years)and body mass index(BMI)(24.39 vs.22.73 kg/m2)between eptifibatide group and tirofiban group.There was no significant difference in coagulation factor function(R),fibrinogen function(K),fibrinolysis function(EPL),comprehensive coagulation index(Cl),arachidonic acid pathway inhibition rate(AA％)and adenosine diphosphate inhibition rate(ADP％).However,the baseline level of residual platelet function MA(ADP)in eptifibatide group was significantly higher than that in tirofiban group(50.79 vs.35.29 mm,P = 0.0026).There was a statistical difference in the platelet aggregation function MA(65.38 vs.62.54 mm,p = 0.0442),the rate of spontaneous hemorrhagic stroke(4.3％vs.0％)and the rate of asymptomatic minor bleeding(26.08％vs.4.1％)in the two groups(P ＜ 0.05).Conclusion:Both eptifibatide and tirofiban can effectively inhibit platelets,but the effect of etifeptide is better than that of tirofiban in preventing intracranial microhemorrhage and asymptomatic cerebral infarction.